Comment | Published:

Rethinking progression of CKD as a process of punctuated equilibrium

Nature Reviews Nephrologyvolume 14pages411412 (2018) | Download Citation

Although most nephrologists spend their days managing patients with acute and chronic kidney disease (CKD), it is useful to occasionally consider the landscape of our current treatment approach. Here, we present the hypothesis that the major mechanisms that drive CKD are changing and will necessitate new approaches to manage this disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Mitch, W. E., Walser, M., Buffington, G. A. & Lemann, J. Jr. A simple method of estimating progression of chronic renal failure. Lancet 2, 1326–1328 (1976).

  2. 2.

    Mogensen, C. E., Christensen, C. K. & Vittinghus, E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2), 64–78 (1983).

  3. 3.

    Polonia, J., Azevedo, A., Monte, M., Silva, J. A. & Bertoquini, S. Annual deterioration of renal function in hypertensive patients with and without diabetes. Vasc. Health Risk Manag. 13, 231–237 (2017).

  4. 4.

    Perera, G. A. Hypertensive vascular disease; description and natural history. J. Chron. Dis. 1, 33–42 (1955).

  5. 5.

    Eldredge, N. & Gould, S. J. in Models in Paleobiology (ed. Schopf, T. J. M.) 82–115 (Cooper and Co., 1972).

  6. 6.

    Stevens, P. E., Levin, A. & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830 (2013).

Download references


Research conducted in the authors’ laboratories is funded by grants from FONACYT, Venezuela (FC-2005000283, to BR-I) and Asociación de Amigos del Riñón (to BR-I) and by the National Institutes of Health NIDDK Institute (1RO1DK109408-01A1 and R01 DK108859-01).

Author information


  1. Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    • Richard J. Johnson
  2. Nephrology Service Hospital Universitario, Universidad del Zulia, Instituto Venezolano de Investigaciones Científicas (IVIC-Zulia), Maracaibo, Venezuela

    • Bernardo Rodriguez-Iturbe


  1. Search for Richard J. Johnson in:

  2. Search for Bernardo Rodriguez-Iturbe in:

Competing interests

R.J.J. is on the Scientific Board of XORT Therapeutics, has patent and patent applications related to lowering uric acid or blocking fructose metabolism in the treatment of hypertension and metabolic disorders, and is a member of Colorado Research Partners, LLC, which is developing inhibitors of fructose metabolism. B.R.I. declares no competing interests.

Corresponding author

Correspondence to Richard J. Johnson.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing